Study of ianalumab plus eltrombopag for children with ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests whether adding ianalumab to eltrombopag helps children with immune thrombocytopenia (ITP) who didn't get better with steroids. It aims to find a new option for kids whose platelet counts are low despite treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 5 and 18 years old.
- They must have primary ITP that did not respond well to steroids (with or without IVIG).
- Their platelet count must be below 30 billion per liter, and their doctor thinks eltrombopag is appropriate.
- They must be up-to-date on routine childhood vaccines per local guidelines.
- They cannot have had other ITP treatments like splenectomy or long-term use of similar drugs beyond one week.
- They must not have serious liver or kidney problems, active infections, or be pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
This trial tests a two-step approach for adults with severe ITP: first a growth factor injection (rhTPO), then a pill (eltrombopag). The goal is to see if this sequence works better than steroids alone to raise platelet counts safely.
This trial tests a drug called belantamab mafodotin for adults with primary immune thrombocytopenia (ITP) whose platelet levels stayed low after trying steroids and another treatment like TPO-RA or rituximab. The goal is to see if it safely raises platelet counts.
This trial tests two ways to raise platelets for people with immune thrombocytopenia (ITP) who did not respond well to a short course of the platelet-boosting drug rhTPO. One group gets a higher dose of rhTPO, the other switches to a different oral medication, eltrombopag. The goal is to see which approach works better to increase platelet counts safely.
This trial tests if a new medicine called QL0911 can help children with chronic ITP who haven't improved with standard treatments. It aims to raise platelet counts and reduce bleeding risk.
Hear when a new Primary Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.